The Gates Foundation is spending $40 million on countries in Africa and other economically backward nations to produce new mRNA vaccines in efforts to prevent against diseases like tuberculosis and malaria.
On Monday, the Bill & Melinda Gates Foundation announced $40 million in funding to "Advance access to mRNA research and vaccine manufacturing technology that will support low-and middle-income countries' capacity to develop high-quality, lifesaving vaccines at scale," according to an Oct. 9 press release.
Quantoom's platform can lead to a more than 50 percent drop in mRNA vaccine development costs compared to traditional mRNA technology, the release said.
Expanding the technology to countries like South Africa and Senegal can lead to the development of low-cost mRNA vaccines for diseases like malaria and tuberculosis.
The $40 million funding adds to the foundation's previous investment worth $55 million in mRNA manufacturing technology.
Scientist Drew Weissman, who won the 2023 Nobel Prize in Medicine for his role in developing the mRNA technology, warned in a 2018 paper that not only did clinical trials of mRNA vaccines produce "More modest [results] in humans than was expected based on animal models," but that the "Side effects were not trivial." Potential Side Effects from COVID-19 mRNA Vaccine A recent study published in Frontiers in Immunology has raised concerns about potential alterations to base functions of a person's immune system by Pfizer's mRNA COVID-19 vaccine.
Last month, Florida's Surgeon General, Dr. Joseph Ladapo, advised people under 65 years of age not to take the new COVID-19 mRNA vaccines, and for those over 65 to discuss risks of the COVID-19 mRNA vaccine with their doctor to decide on their health approach during the pandemic.
No comments:
Post a Comment